Open | - |
Close | - |
Volume / Avg. | 0 / 1.184M |
Day Range | - - - |
52 Wk Range | 15.450 - 33.310 |
Market Cap | $2.790B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 53 |
Short Interest | 9.21% |
Days to Cover | 10.38 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Denali Therapeutics (NASDAQ: DNLI) through any online brokerage.
Other companies in Denali Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), MoonLake (NASDAQ:MLTX), SpringWorks Therapeutics (NASDAQ:SWTX), TG Therapeutics (NASDAQ:TGTX) and Arrowhead Pharma (NASDAQ:ARWR).
The latest price target for Denali Therapeutics (NASDAQ: DNLI) was reported by Goldman Sachs on Thursday, February 29, 2024. The analyst firm set a price target for 50.00 expecting DNLI to rise to within 12 months (a possible 149.38% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Denali Therapeutics (NASDAQ: DNLI) is $20.05 last updated March 18, 2024 at 4:39 PM EDT.
There are no upcoming dividends for Denali Therapeutics.
Denali Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Denali Therapeutics.
Denali Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.